Back to Journals » Drug Design, Development and Therapy » Volume 8

Potent tumor targeting drug release system comprising MMP-2 specific peptide fragment with self-assembling characteristics

Authors Hua D, Kong W, Zheng X, Zhou Z, Yu B, Li Y, Wang Y, Yang X, Liu C, Tang L, Li Y, Gong M

Received 6 May 2014

Accepted for publication 28 June 2014

Published 14 October 2014 Volume 2014:8 Pages 1839—1849


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Dan Hua,1 Weiling Kong,2 Xuemin Zheng,2 Zhixing Zhou,2 Bing Yu,2 Yazhou Li,2 Yuli Wang,2 Xue Yang,2 Changxiao Liu,2 Lida Tang,2 Ying Li,3 Min Gong2

1School of Pharmacy, Tianjin Medical University, 2Tianjin Institute of Pharmaceutical Research, State Key Laboratory of Drug Delivery and Pharmacokinetics, 3Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China

Abstract: Self-assembling peptides are capable of forming a complex containing a cavity where cytotoxic agents can be wrapped in a self-assembling manner. These complexes are beneficial for improving the pharmacological properties and pharmacokinetics of cytotoxic agents, such as doxorubicin and paclitaxel. In the present study, this self-assembling feature was successfully integrated into a hexapeptide with matrix metalloproteinase (MMP)-2 specific targeting activity, producing a supramolecule possessing controlled drug release characteristics. The MMP-2 specific substrate fragment, PVGLIG, makes this supramolecule disassociate in the presence of MMP-2, and this system is considered to be a powerful tool for the treatment of tumors with high expression of MMP-2 or tumor metastasis. Our findings show that this modified self-assembling peptide with the PVGLIG fragment was able to significantly enhance specificity against HT1080 cells, a tumor cell line with high expression of MMP-2. In addition, residence time of the complex in blood was prolonged since paclitaxel was wrapped into the supramolecule. Our results suggest that the modified MMP-2 specific substrate, SAMTA7, could act as a controlled and sustained drug carrier for treatment of tumors with high expression of MMP-2 and for tumor metastasis.

Keywords: matrix metalloproteinase, self-assembly, drug targeting system, paclitaxel

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]